European Regulator Deals Blow For Lilly’s Alzheimer’s Drug Kisunla

 
• By Francesca Bruce
  
Lilly will request a CHMP re-examination of its Alzheimer's disease drug Kisunla (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Product Reviews